MedTrace Logo

The 3q25 rs2305619 Polymorphism Associates With Microvascular Obstruction in STEMI

NCT03907722 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 217

Last updated 2019-04-11

No results posted yet for this study

Summary

The investigators enrolled 217 patients with acute STEMI undergoing primary PCI. The rs2305619 polymorphism was evaluated by real time PCR and plasma PTX3 concentration was assessed by human PTX3 ELISA kit.

Conditions

  • STEMI
  • Microvascular Coronary Artery Disease

Interventions

OTHER

Long pentraxin 3

Primary PCI

Sponsors & Collaborators

  • Indonesian Cardiovascular Research Center

    lead OTHER

Principal Investigators

  • Surya Dharma, MD, PhD · Indonesian Cardiovascular Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2018-08-02
Completion
2018-09-03

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03907722 on ClinicalTrials.gov